
    
      A study to assess the pharmacokinetics of single escalating doses of inhaled GSK961081 DPI (a
      dual pharmacophore) in healthy subjects (Part 1) and a randomised, double-blind, double
      dummy, crossover (incomplete block) study to assess the safety, tolerability,
      pharmacodynamics (pulmonary and systemic) and pharmacokinetics of 14 days dosing with inhaled
      GSK961081 DPI compared with placebo and tiotropium plus salmeterol in patients with COPD
      (Part 2).
    
  